Research Papers:

Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma

Nazim Benzerdjeb _, Henri Sevestre, Ahmed Ahidouch and Halima Ouadid-Ahidouch

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:81588-81597. https://doi.org/10.18632/oncotarget.13149

Metrics: PDF 1905 views  |   HTML 1680 views  |   ?  


Nazim Benzerdjeb1,2, Henri Sevestre2, Ahmed Ahidouch2,3, Halima Ouadid-Ahidouch1

1Laboratory of Cellular and Molecular Physiology, LPCM: EA 4667, SFR CAP-SANTE (FED 4231), UFR of Sciences, Amiens, France

2Department of Pathology, Amiens University Hospital, Amiens, France

3Department of Biology, Ibn Zohr University, Agadir, Morocco

Correspondence to:

Halima Ouadid-Ahidouch, email: [email protected]

Nazim Benzerdjeb, email: [email protected]

Keywords: orai3, lung adenocarcinoma, prognostic marker, survival

Received: June 11, 2016    Accepted: October 17, 2016    Published: November 07, 2016


Orai3 channel has emerged as important player in malignant transformation. Indeed, its expression is increased in cancer and favors cell proliferation and survival by permitting calcium influx. In this study, Orai3 was overexpressed in lung adenocarcinoma as compared to their matched non-tumour samples and was associated with tumoural aggressiveness. Moreover, its expression was associated with estrogen receptor alpha (ERα) expression and visceral pleural invasion in multivariate analysis. Furthermore, both the overall survival (OS) median and the metastasis free survival (MFS) median of tumors with high Orai3 expression were lower than in low Orai3 expression regardless of cancer stage (35.01 months vs. 51.11 months for OS and 46.01 months vs. 62.04 months for MFS). In conclusion, Orai3 protein level constitutes an independent prognostic marker in lung adenocarcinoma, and a novel prognostic marker that could help selecting the patients with worst prognosis to be treated with adjuvant chemotherapy in resectable stage.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13149